Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.
Share Information
Market Value, $K:
67,380
Shares Outstanding, K:
15,970
% Held by Insiders:
53.30%
% Institutional Shareholders:
1.58%
Last Quarter Sales, $M:
N/C
Last Quarter Net Income, $M:
-3.20
Last Quarter EPS:
-0.22
P/E Ratio:
0.00
Annual EPS, $:
-0.77
Most Recent Earnings, $:
Annual Dividend Rate, $:
0
Most Recent Dividend:
Annual Dividend Yield, %:
0%
Most Recent Split:
1-6 on 03/23/12
Fundamental information provided by Zacks Investment Research, Inc.
Zacks does not represent, warrant,
or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever
to any party on account of any incompleteness of, inaccuracies in or untimeliness of the Zacks content provided
hereunder, or for any delay in reporting such data. Zacks expressly disclaims all warranties of fitness of the
Zacks content or computations and analyses thereof for a particular purpose or use.
